Displaying drugs 1051 - 1075 of 2615 in total
GCS-100
Investigational
OCU-100
Investigational
PTX-100
Investigational
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
Matched Synonyms: … Adeno-associated virus serotype 9 vector encoding the Dok7 protein …
Matched Description: … AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human …
Matched Description: … AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human …
LX-1004
Investigational
CAN-106
CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
Investigational
AVB-101
AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.
Investigational
Idroxioleic acid
Investigational
Matched Synonyms: … (z)-2-hydroxyoctadec-9-enoic acid ... Cis-2-hydroxy-9-octadecenoic acid ... 9-octadecenoic acid, 2-hydroxy-, (9z)- …
Matched Iupac: … (9Z)-2-hydroxyoctadec-9-enoic acid …
Matched Iupac: … (9Z)-2-hydroxyoctadec-9-enoic acid …
PRTX-100
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the...
Investigational
Dalotuzumab
Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Investigational
SQ-109
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
PR-104
Investigational
PX-102
PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).
Investigational
GI-101
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
Investigational
SP-101
Investigational
CM-101
Investigational
GS-100
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
Matched Description: … GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression …
Uzansertib
Uzansertib is under investigation in clinical trial NCT02587598 (Study of INCB053914 in Subjects With Advanced Malignancies).
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
BL-1020
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Investigational
ATX-101
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
NOX-100
NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple...
Investigational
Displaying drugs 1051 - 1075 of 2615 in total